ILLUMINA INC (ILMN) Fundamental Analysis & Valuation

NASDAQ:ILMN • US4523271090

128.97 USD
-0.59 (-0.46%)
At close: Mar 4, 2026
131 USD
+2.03 (+1.57%)
After Hours: 3/4/2026, 8:00:03 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ILMN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

Taking everything into account, ILMN scores 6 out of 10 in our fundamental rating. ILMN was compared to 57 industry peers in the Life Sciences Tools & Services industry. Both the health and profitability get an excellent rating, making ILMN a very profitable company, without any liquidiy or solvency issues. ILMN has a correct valuation and a medium growth rate. With these ratings, ILMN could be worth investigating further for quality investing!.


Dividend Valuation Growth Profitability Health

7

1. ILMN Profitability Analysis

1.1 Basic Checks

  • ILMN had positive earnings in the past year.
  • ILMN had a positive operating cash flow in the past year.
  • In multiple years ILMN reported negative net income over the last 5 years.
  • ILMN had a positive operating cash flow in each of the past 5 years.
ILMN Yearly Net Income VS EBIT VS OCF VS FCFILMN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B -1B -2B -3B -4B

1.2 Ratios

  • ILMN has a better Return On Assets (12.79%) than 96.49% of its industry peers.
  • The Return On Equity of ILMN (31.22%) is better than 96.49% of its industry peers.
  • ILMN has a better Return On Invested Capital (13.63%) than 92.98% of its industry peers.
Industry RankSector Rank
ROA 12.79%
ROE 31.22%
ROIC 13.63%
ROA(3y)-6.03%
ROA(5y)-9.81%
ROE(3y)-13.51%
ROE(5y)-20.03%
ROIC(3y)N/A
ROIC(5y)N/A
ILMN Yearly ROA, ROE, ROICILMN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40 -60

1.3 Margins

  • With an excellent Profit Margin value of 19.57%, ILMN belongs to the best of the industry, outperforming 92.98% of the companies in the same industry.
  • In the last couple of years the Profit Margin of ILMN has remained more or less at the same level.
  • Looking at the Operating Margin, with a value of 20.29%, ILMN belongs to the top of the industry, outperforming 87.72% of the companies in the same industry.
  • In the last couple of years the Operating Margin of ILMN has grown nicely.
  • ILMN has a better Gross Margin (66.61%) than 91.23% of its industry peers.
  • ILMN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 20.29%
PM (TTM) 19.57%
GM 66.61%
OM growth 3Y36.82%
OM growth 5Y2.01%
PM growth 3YN/A
PM growth 5Y-0.68%
GM growth 3Y0.64%
GM growth 5Y-0.57%
ILMN Yearly Profit, Operating, Gross MarginsILMN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ILMN Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ILMN is creating some value.
  • The number of shares outstanding for ILMN has been reduced compared to 1 year ago.
  • ILMN has more shares outstanding than it did 5 years ago.
  • ILMN has a better debt/assets ratio than last year.
ILMN Yearly Shares OutstandingILMN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
ILMN Yearly Total Debt VS Total AssetsILMN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.2 Solvency

  • An Altman-Z score of 4.35 indicates that ILMN is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 4.35, ILMN belongs to the top of the industry, outperforming 84.21% of the companies in the same industry.
  • ILMN has a debt to FCF ratio of 2.14. This is a good value and a sign of high solvency as ILMN would need 2.14 years to pay back of all of its debts.
  • ILMN has a better Debt to FCF ratio (2.14) than 89.47% of its industry peers.
  • A Debt/Equity ratio of 0.55 indicates that ILMN is somewhat dependend on debt financing.
  • The Debt to Equity ratio of ILMN (0.55) is worse than 64.91% of its industry peers.
  • Although ILMN does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 2.14
Altman-Z 4.35
ROIC/WACC1.28
WACC10.62%
ILMN Yearly LT Debt VS Equity VS FCFILMN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B 8B 10B

2.3 Liquidity

  • A Current Ratio of 2.08 indicates that ILMN has no problem at all paying its short term obligations.
  • The Current ratio of ILMN (2.08) is comparable to the rest of the industry.
  • ILMN has a Quick Ratio of 1.72. This is a normal value and indicates that ILMN is financially healthy and should not expect problems in meeting its short term obligations.
  • ILMN's Quick ratio of 1.72 is in line compared to the rest of the industry. ILMN outperforms 43.86% of its industry peers.
Industry RankSector Rank
Current Ratio 2.08
Quick Ratio 1.72
ILMN Yearly Current Assets VS Current LiabilitesILMN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. ILMN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 97.96% over the past year.
  • The Earnings Per Share has been growing slightly by 1.51% on average over the past years.
  • Looking at the last year, ILMN shows a decrease in Revenue. The Revenue has decreased by -0.66% in the last year.
  • The Revenue has been growing slightly by 6.04% on average over the past years.
EPS 1Y (TTM)97.96%
EPS 3Y31.77%
EPS 5Y1.51%
EPS Q2Q%56.98%
Revenue 1Y (TTM)-0.66%
Revenue growth 3Y-1.78%
Revenue growth 5Y6.04%
Sales Q2Q%4.98%

3.2 Future

  • Based on estimates for the next years, ILMN will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.14% on average per year.
  • Based on estimates for the next years, ILMN will show a small growth in Revenue. The Revenue will grow by 6.06% on average per year.
EPS Next Y6.75%
EPS Next 2Y10.5%
EPS Next 3Y9.64%
EPS Next 5Y12.14%
Revenue Next Year5.78%
Revenue Next 2Y5.64%
Revenue Next 3Y5.85%
Revenue Next 5Y6.06%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ILMN Yearly Revenue VS EstimatesILMN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
ILMN Yearly EPS VS EstimatesILMN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

4

4. ILMN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 26.59, which means the current valuation is very expensive for ILMN.
  • Based on the Price/Earnings ratio, ILMN is valued a bit cheaper than 70.18% of the companies in the same industry.
  • ILMN is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.03, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 24.91, the valuation of ILMN can be described as rather expensive.
  • ILMN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. ILMN is cheaper than 71.93% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of ILMN to the average of the S&P500 Index (25.11), we can say ILMN is valued inline with the index average.
Industry RankSector Rank
PE 26.59
Fwd PE 24.91
ILMN Price Earnings VS Forward Price EarningsILMN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ILMN is valued a bit cheaper than the industry average as 77.19% of the companies are valued more expensively.
  • 84.21% of the companies in the same industry are more expensive than ILMN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 21.17
EV/EBITDA 17.32
ILMN Per share dataILMN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of ILMN may justify a higher PE ratio.
PEG (NY)3.94
PEG (5Y)17.62
EPS Next 2Y10.5%
EPS Next 3Y9.64%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ILMN Dividend Analysis

5.1 Amount

  • No dividends for ILMN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ILMN Fundamentals: All Metrics, Ratios and Statistics

ILLUMINA INC

NASDAQ:ILMN (3/4/2026, 8:00:03 PM)

After market: 131 +2.03 (+1.57%)

128.97

-0.59 (-0.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-05
Earnings (Next)05-06
Inst Owners104.7%
Inst Owner Change-0.86%
Ins Owners0.17%
Ins Owner Change-0.38%
Market Cap19.71B
Revenue(TTM)4.34B
Net Income(TTM)850.00M
Analysts72.31
Price Target138.42 (7.33%)
Short Float %5.2%
Short Ratio3.68
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.14%
Min EPS beat(2)7.62%
Max EPS beat(2)12.65%
EPS beat(4)4
Avg EPS beat(4)9.22%
Min EPS beat(4)1.33%
Max EPS beat(4)15.27%
EPS beat(8)6
Avg EPS beat(8)14.29%
EPS beat(12)10
Avg EPS beat(12)229.93%
EPS beat(16)13
Avg EPS beat(16)175.4%
Revenue beat(2)1
Avg Revenue beat(2)1.24%
Min Revenue beat(2)-0.28%
Max Revenue beat(2)2.75%
Revenue beat(4)1
Avg Revenue beat(4)0.08%
Min Revenue beat(4)-1.21%
Max Revenue beat(4)2.75%
Revenue beat(8)3
Avg Revenue beat(8)-0.09%
Revenue beat(12)5
Avg Revenue beat(12)-0.28%
Revenue beat(16)5
Avg Revenue beat(16)-0.88%
PT rev (1m)4.67%
PT rev (3m)14.9%
EPS NQ rev (1m)-6.53%
EPS NQ rev (3m)-4.42%
EPS NY rev (1m)0.04%
EPS NY rev (3m)2.37%
Revenue NQ rev (1m)1.3%
Revenue NQ rev (3m)1.96%
Revenue NY rev (1m)3.03%
Revenue NY rev (3m)3.79%
Valuation
Industry RankSector Rank
PE 26.59
Fwd PE 24.91
P/S 4.54
P/FCF 21.17
P/OCF 18.26
P/B 7.24
P/tB 14.08
EV/EBITDA 17.32
EPS(TTM)4.85
EY3.76%
EPS(NY)5.18
Fwd EY4.01%
FCF(TTM)6.09
FCFY4.72%
OCF(TTM)7.06
OCFY5.48%
SpS28.42
BVpS17.82
TBVpS9.16
PEG (NY)3.94
PEG (5Y)17.62
Graham Number44.1
Profitability
Industry RankSector Rank
ROA 12.79%
ROE 31.22%
ROCE 17.41%
ROIC 13.63%
ROICexc 20.13%
ROICexgc 32.79%
OM 20.29%
PM (TTM) 19.57%
GM 66.61%
FCFM 21.44%
ROA(3y)-6.03%
ROA(5y)-9.81%
ROE(3y)-13.51%
ROE(5y)-20.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y1.94%
ROICexgc growth 5Y5.2%
ROICexc growth 3Y74.03%
ROICexc growth 5Y4.4%
OM growth 3Y36.82%
OM growth 5Y2.01%
PM growth 3YN/A
PM growth 5Y-0.68%
GM growth 3Y0.64%
GM growth 5Y-0.57%
F-Score8
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 2.14
Debt/EBITDA 1.29
Cap/Depr 54.81%
Cap/Sales 3.41%
Interest Coverage 9.27
Cash Conversion 93.74%
Profit Quality 109.53%
Current Ratio 2.08
Quick Ratio 1.72
Altman-Z 4.35
F-Score8
WACC10.62%
ROIC/WACC1.28
Cap/Depr(3y)45.45%
Cap/Depr(5y)67.5%
Cap/Sales(3y)3.56%
Cap/Sales(5y)5.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.96%
EPS 3Y31.77%
EPS 5Y1.51%
EPS Q2Q%56.98%
EPS Next Y6.75%
EPS Next 2Y10.5%
EPS Next 3Y9.64%
EPS Next 5Y12.14%
Revenue 1Y (TTM)-0.66%
Revenue growth 3Y-1.78%
Revenue growth 5Y6.04%
Sales Q2Q%4.98%
Revenue Next Year5.78%
Revenue Next 2Y5.64%
Revenue Next 3Y5.85%
Revenue Next 5Y6.06%
EBIT growth 1Y36.38%
EBIT growth 3Y34.38%
EBIT growth 5Y8.17%
EBIT Next Year32.05%
EBIT Next 3Y17.05%
EBIT Next 5Y16.57%
FCF growth 1Y31.31%
FCF growth 3YN/A
FCF growth 5Y0.88%
OCF growth 1Y28.91%
OCF growth 3Y40.15%
OCF growth 5Y-0.02%

ILLUMINA INC / ILMN FAQ

Can you provide the ChartMill fundamental rating for ILLUMINA INC?

ChartMill assigns a fundamental rating of 6 / 10 to ILMN.


Can you provide the valuation status for ILLUMINA INC?

ChartMill assigns a valuation rating of 4 / 10 to ILLUMINA INC (ILMN). This can be considered as Fairly Valued.


How profitable is ILLUMINA INC (ILMN) stock?

ILLUMINA INC (ILMN) has a profitability rating of 7 / 10.


What is the financial health of ILLUMINA INC (ILMN) stock?

The financial health rating of ILLUMINA INC (ILMN) is 7 / 10.


What is the expected EPS growth for ILLUMINA INC (ILMN) stock?

The Earnings per Share (EPS) of ILLUMINA INC (ILMN) is expected to grow by 6.75% in the next year.